Benitec Biopharma Ltd ADR (BNTC) - Net Assets
Based on the latest financial reports, Benitec Biopharma Ltd ADR (BNTC) has net assets worth $187.36 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($190.68 Million) and total liabilities ($3.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BNTC cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $187.36 Million |
| % of Total Assets | 98.26% |
| Annual Growth Rate | 10.12% |
| 5-Year Change | 386.23% |
| 10-Year Change | 591.65% |
| Growth Volatility | 6438.87 |
Benitec Biopharma Ltd ADR - Net Assets Trend (2013–2025)
This chart illustrates how Benitec Biopharma Ltd ADR's net assets have evolved over time, based on quarterly financial data. Also explore Benitec Biopharma Ltd ADR balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Benitec Biopharma Ltd ADR (2013–2025)
The table below shows the annual net assets of Benitec Biopharma Ltd ADR from 2013 to 2025. For live valuation and market cap data, see how much is Benitec Biopharma Ltd ADR worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $97.30 Million | +105.92% |
| 2024-06-30 | $47.25 Million | +23290.10% |
| 2023-06-30 | $202.00K | -92.99% |
| 2022-06-30 | $2.88 Million | -85.60% |
| 2021-06-30 | $20.01 Million | +95.45% |
| 2020-06-30 | $10.24 Million | -38.21% |
| 2019-06-30 | $16.57 Million | +20.34% |
| 2018-06-30 | $13.77 Million | -16.68% |
| 2017-06-30 | $16.53 Million | +17.48% |
| 2016-06-30 | $14.07 Million | -23.19% |
| 2015-06-30 | $18.31 Million | -18.53% |
| 2014-06-30 | $22.48 Million | -26.56% |
| 2013-06-30 | $30.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Benitec Biopharma Ltd ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14030537021.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.00% |
| Other Comprehensive Income | $-839.00K | -0.86% |
| Other Components | $326.31 Million | 335.38% |
| Total Equity | $97.30 Million | 100.00% |
Benitec Biopharma Ltd ADR Competitors by Market Cap
The table below lists competitors of Benitec Biopharma Ltd ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Attica Holdings S.A.
AT:ATTICA
|
$420.67 Million |
|
MediaAlpha Inc.
NYSE:MAX
|
$420.67 Million |
|
Concord Securities Co Ltd
TWO:6016
|
$420.73 Million |
|
The York Water Company
NASDAQ:YORW
|
$420.77 Million |
|
SMS Electric Co Ltd Zhengzhou
SHE:002857
|
$420.55 Million |
|
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd
SHE:300534
|
$420.36 Million |
|
Liaoning Shidai Wanheng Co Ltd
SHG:600241
|
$420.32 Million |
|
RCE Capital Berhad
KLSE:9296
|
$420.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Benitec Biopharma Ltd ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 47,248,000 to 97,295,000, a change of 50,047,000 (105.9%).
- Net loss of 37,917,000 reduced equity.
- New share issuances of 30,460,000 increased equity.
- Other comprehensive income increased equity by 53,000.
- Other factors increased equity by 57,451,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-37.92 Million | -38.97% |
| Share Issuances | $30.46 Million | +31.31% |
| Other Comprehensive Income | $53.00K | +0.05% |
| Other Changes | $57.45 Million | +59.05% |
| Total Change | $- | 105.92% |
Book Value vs Market Value Analysis
This analysis compares Benitec Biopharma Ltd ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.73x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.01x to 4.73x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-06-30 | $1726.62 | $12.70 | x |
| 2014-06-30 | $316.96 | $12.70 | x |
| 2015-06-30 | $202.16 | $12.70 | x |
| 2016-06-30 | $126.03 | $12.70 | x |
| 2017-06-30 | $120.11 | $12.70 | x |
| 2018-06-30 | $83.42 | $12.70 | x |
| 2019-06-30 | $82.20 | $12.70 | x |
| 2020-06-30 | $42.61 | $12.70 | x |
| 2021-06-30 | $19.80 | $12.70 | x |
| 2022-06-30 | $1.50 | $12.70 | x |
| 2023-06-30 | $0.15 | $12.70 | x |
| 2024-06-30 | $4.60 | $12.70 | x |
| 2025-06-30 | $2.69 | $12.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Benitec Biopharma Ltd ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -38.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.02x
- Recent ROE (-38.97%) is above the historical average (-836.26%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -20.99% | -1177.09% | 0.02x | 1.03x | $-9.48 Million |
| 2014 | -48.20% | -1064.66% | 0.04x | 1.07x | $-13.08 Million |
| 2015 | -48.20% | -1064.66% | 0.04x | 1.07x | $-10.66 Million |
| 2016 | -131.54% | -5340.09% | 0.02x | 1.06x | $-19.91 Million |
| 2017 | -26.46% | -970.99% | 0.03x | 1.05x | $-6.03 Million |
| 2018 | -62.10% | -1877.42% | 0.03x | 1.14x | $-9.93 Million |
| 2019 | 17.30% | 25.34% | 0.59x | 1.16x | $1.21 Million |
| 2020 | -80.82% | -8529.90% | 0.01x | 1.15x | $-9.30 Million |
| 2021 | -69.38% | -23528.81% | 0.00x | 1.07x | $-15.88 Million |
| 2022 | -631.78% | -24942.47% | 0.01x | 2.07x | $-18.50 Million |
| 2023 | -9684.16% | -26082.67% | 0.02x | 22.10x | $-19.58 Million |
| 2024 | -46.04% | -10069.91% | 0.00x | 1.11x | $-26.48 Million |
| 2025 | -38.97% | 0.00% | 0.00x | 1.02x | $-47.65 Million |
Industry Comparison
This section compares Benitec Biopharma Ltd ADR's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Benitec Biopharma Ltd ADR (BNTC) | $187.36 Million | -20.99% | 0.02x | $420.65 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Benitec Biopharma Ltd ADR
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single a… Read more